Objective: This study aims to investigate the effect of octreotide combined with ulinastatin on the serum endotoxin and intestinal mucosal permeability in patients with severe pancreatitis.
Methods: A total of 88 patients with severe pancreatitis were randomly selected in our hospital from January 2015 to June 2016. They were then randomly assigned to either the observation group (n=44) or the control group (n=44) using the random number method. The patients in the control group were treated with octreotide, whereas those in the observation group were given octreotide combined with ulinastatin. The serum endotoxin and hypersensitive C Reactive Protein (hs-CRP) levels as well as intestinal mucosal permeability of the two groups were investigated before and after treatment.
Results: Before treatment, no significant difference was observed in the serum endotoxin, hs-CRP, plasma Diamine Oxidase (DAO), and Lactulose/Mannitol (L/M) levels of patients between the two groups (P>0.05). However, the endotoxin and hs-CRP levels of the patients in the two groups were significantly lower after treatment than those before treatment (P<0.05). After treatment, the plasma DAO levels of the patients in the two groups were significantly lower than those before treatment (P<0.05), and their L/M levels were significantly higher than those before treatment (P<0.05). However, the serum endotoxin, hs-CRP, plasma DAO, and L/M levels of the patients in the observation group were significantly lower than those in the control group (P<0.05).
Conclusion: Octreotide combined with ulinastatin can significantly decrease the serum endotoxin level of patients with severe pancreatitis. Furthermore, this treatment can help in the restoration of intestinal mucosal function barrier in patients.Author(s): Zhi-Yu Yang, Long-Peng Su, Qun Xiang, Xin-Yu Yang, Sai Chen, Sai-Dong Zhou, Hui Li